EA200100823A1 - S-нитрозотиолы в качестве агентов для лечения нарушений кровообращения - Google Patents

S-нитрозотиолы в качестве агентов для лечения нарушений кровообращения

Info

Publication number
EA200100823A1
EA200100823A1 EA200100823A EA200100823A EA200100823A1 EA 200100823 A1 EA200100823 A1 EA 200100823A1 EA 200100823 A EA200100823 A EA 200100823A EA 200100823 A EA200100823 A EA 200100823A EA 200100823 A1 EA200100823 A1 EA 200100823A1
Authority
EA
Eurasian Patent Office
Prior art keywords
residue
group
treatment
glutamic acid
hydroxyl group
Prior art date
Application number
EA200100823A
Other languages
English (en)
Other versions
EA003577B1 (ru
Inventor
Хосе Репольес Молинер
Эдуардо Салас Перес-Расилья
Франсиско Пубиль Кой
Хуан Антонио Серда Риудаветс
Кристина Негрье Рофес
Лидия Кабеса Льоренте
Алисия Феррер Сисо
Нурия Триас Адроер
Марсель.ли Карбо Банус
Хесус Мурат Морено
Педро Мичелена Льягуно
Original Assignee
Ласер, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ласер, С.А. filed Critical Ласер, С.А.
Publication of EA200100823A1 publication Critical patent/EA200100823A1/ru
Publication of EA003577B1 publication Critical patent/EA003577B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Новые S-нитрозотиоловые производные пеницилламина или глутатиона и их фармацевтически приемлемые соли, которые соответствуют следующей общей формуле (I)в которой A и B являются фенильными группами или же вместе образуют остаток -CH-Q-CH-, образующий шестичленное кольцо, в котором Q представляет собой атом кислорода или серы, или группу N-R, в которой Rявляется водородом или алкильной группой C-C;Rявляется ацильным остатком, который может быть алифатической ацильной группой C-Cили остатком глутаминовой кислоты, связанным через его неаминокислотный карбоксил;Rявляется гидроксильной группой или остатком глицина, связанным через его пептидную связь;при условии, что когда Rявляется алифатическим ацильным остатком, тогда Rявляется гидроксильной группой, а когда Rявляется остатком глутаминовой кислоты, тогда Rявляется остатком глицина. Указанные новые соединения обладают сосудорасширяющей активностью и ингибируют агрегацию тромбоцитов, что делает их применимыми для лечения дисфункций системы кровообращения, в частности, на уровне сердечно-сосудистой системы.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100823A 1999-01-27 2000-01-19 S-нитрозотиолы в качестве агентов для лечения нарушений кровообращения EA003577B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009900159A ES2147162B1 (es) 1999-01-27 1999-01-27 "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias".
PCT/ES2000/000019 WO2000044714A1 (es) 1999-01-27 2000-01-19 S-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias

Publications (2)

Publication Number Publication Date
EA200100823A1 true EA200100823A1 (ru) 2002-02-28
EA003577B1 EA003577B1 (ru) 2003-06-26

Family

ID=8307080

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100823A EA003577B1 (ru) 1999-01-27 2000-01-19 S-нитрозотиолы в качестве агентов для лечения нарушений кровообращения

Country Status (37)

Country Link
US (1) US6800612B2 (ru)
EP (1) EP1157987B1 (ru)
JP (1) JP3795330B2 (ru)
KR (1) KR100671878B1 (ru)
CN (1) CN1166631C (ru)
AP (1) AP1439A (ru)
AT (1) ATE249428T1 (ru)
AU (1) AU764725B2 (ru)
BG (1) BG64983B1 (ru)
BR (1) BR0007395B1 (ru)
CA (1) CA2359027C (ru)
CU (1) CU23098A3 (ru)
CZ (1) CZ298871B6 (ru)
DE (2) DE10083902T1 (ru)
DK (1) DK1157987T3 (ru)
EA (1) EA003577B1 (ru)
EE (1) EE04524B1 (ru)
ES (2) ES2147162B1 (ru)
GB (1) GB2363604B (ru)
GE (1) GEP20043220B (ru)
HK (1) HK1043586A1 (ru)
HR (1) HRP20010562B1 (ru)
HU (1) HUP0105203A3 (ru)
ID (1) ID29777A (ru)
IL (1) IL144381A (ru)
IS (1) IS2153B (ru)
MX (1) MXPA01007570A (ru)
NO (1) NO326806B1 (ru)
NZ (1) NZ513162A (ru)
OA (1) OA11823A (ru)
PL (1) PL202372B1 (ru)
PT (1) PT1157987E (ru)
RS (1) RS50072B (ru)
SI (1) SI1157987T1 (ru)
TR (1) TR200102003T2 (ru)
WO (1) WO2000044714A1 (ru)
ZA (1) ZA200106182B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2173044B1 (es) * 2001-03-13 2004-01-16 Lacer Sa Derivados de glicina, n-(n-l-gamma-glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones.
WO2005030135A2 (en) * 2003-09-26 2005-04-07 Nitromed, Inc. Nitrosated glutamic acid compounds, compositions and methods of use
EP1939179A1 (en) * 2006-12-28 2008-07-02 Lacer, S.A. Stable S-nitrosothiols, method of synthesis and use
WO2009050527A1 (en) 2007-10-17 2009-04-23 Biotech Hungary Kutató És Fejlesztési Kft. Pharmaceutical composition comprising s-nitrosoglutathione and polysaccharide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37839A (en) * 1863-03-03 Improved spoke-machine
GB1567561A (en) 1977-01-18 1980-05-14 Ucb Sa Amino-spiro(oxa-(orthia)cycloalkane-penam) - carboxylic acids
GB2052497B (en) 1979-06-25 1983-06-29 Ucb Sa 6 - amino - spiro - (penam - 2,4' - piperidine) - 3 - carboxylic acid derivatives
DE3805965A1 (de) 1988-02-25 1989-09-07 Tamas Geb Szenasi Eszter Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
US5025001A (en) 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
EP0412699B1 (en) * 1989-08-07 1994-04-27 Takeda Chemical Industries, Ltd. Nitrosothiol derivatives, their production and use
WO1991016337A1 (en) 1990-04-26 1991-10-31 Senju Pharmaceutical Co., Ltd. S-(lower fatty acid)-substituted glutathione derivative
US5187305A (en) * 1990-11-26 1993-02-16 Glaxo Inc. S-nitroso-N-alkonoylpenicillamines
EP1023900B1 (en) 1991-11-14 2005-03-16 The Brigham And Women's Hospital, Inc. Pharmaceutical composition containing S-nitroso-lipoproteins and use thereof
FI933472A (fi) 1992-08-07 1994-02-08 Sankyo Co Peptider med foermaoga att inhibera effekten av HIV-proteas, deras framstaellning och terapeutiska anvaendning
WO1995007691A1 (en) * 1993-09-17 1995-03-23 Brigham And Women's Hospital Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
US5728705A (en) 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
ATE192922T1 (de) 1993-11-02 2000-06-15 Us Health Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden
GB9423868D0 (en) 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
AU6782198A (en) 1997-03-27 1998-10-20 Trustees Of Boston University Novel antiplatelet agent

Also Published As

Publication number Publication date
SI1157987T1 (en) 2004-02-29
GB2363604B (en) 2003-09-10
IL144381A (en) 2005-08-31
HUP0105203A3 (en) 2002-08-28
KR20010101767A (ko) 2001-11-14
IS6020A (is) 2001-07-23
GB0120581D0 (en) 2001-10-17
AU764725B2 (en) 2003-08-28
CN1166631C (zh) 2004-09-15
ZA200106182B (en) 2002-10-28
CZ20012678A3 (cs) 2001-10-17
BG64983B1 (bg) 2006-11-30
NO20013385L (no) 2001-09-17
BR0007395A (pt) 2001-10-30
TR200102003T2 (tr) 2001-12-21
AP2001002247A0 (en) 2001-09-30
JP2002535385A (ja) 2002-10-22
NO326806B1 (no) 2009-02-16
BR0007395B1 (pt) 2010-11-16
CA2359027A1 (en) 2000-08-03
HUP0105203A2 (en) 2002-06-29
ES2206178T3 (es) 2004-05-16
EE200100389A (et) 2002-12-16
EA003577B1 (ru) 2003-06-26
GEP20043220B (en) 2004-04-26
DE60005154T2 (de) 2004-07-08
HK1043586A1 (zh) 2002-09-20
PL349006A1 (en) 2002-06-17
EP1157987A1 (en) 2001-11-28
BG105824A (en) 2002-06-28
RS50072B (sr) 2009-01-22
IS2153B (is) 2006-10-13
DK1157987T3 (da) 2003-11-24
GB2363604A (en) 2002-01-02
ES2147162A1 (es) 2000-08-16
EE04524B1 (et) 2005-08-15
NO20013385D0 (no) 2001-07-06
NZ513162A (en) 2003-01-31
ATE249428T1 (de) 2003-09-15
US20020058629A1 (en) 2002-05-16
IL144381A0 (en) 2002-05-23
DE10083902T1 (de) 2002-01-10
CA2359027C (en) 2008-10-28
DE60005154D1 (de) 2003-10-16
CU23098A3 (es) 2005-11-18
ES2147162B1 (es) 2001-03-16
CZ298871B6 (cs) 2008-02-27
MXPA01007570A (es) 2003-05-14
OA11823A (en) 2005-08-16
AP1439A (en) 2005-06-27
CN1337946A (zh) 2002-02-27
AU3046000A (en) 2000-08-18
WO2000044714A1 (es) 2000-08-03
HRP20010562A2 (en) 2002-08-31
JP3795330B2 (ja) 2006-07-12
EP1157987B1 (en) 2003-09-10
PT1157987E (pt) 2004-01-30
YU53601A (sh) 2004-03-12
ID29777A (id) 2001-10-11
PL202372B1 (pl) 2009-06-30
KR100671878B1 (ko) 2007-01-19
US6800612B2 (en) 2004-10-05
HRP20010562B1 (en) 2010-08-31

Similar Documents

Publication Publication Date Title
RU2006134003A (ru) Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
EA200301094A1 (ru) Аминопроизводные как ингибиторы протеазы
EA200200619A1 (ru) Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
EA200300792A1 (ru) Хиназолины в качестве ингибиторов ммр-13
RU94041739A (ru) Производные сульфонамида, фармацевтическая композиция и способы лечения и профилактики заболеваний. новые сульфонамидные антагонисты рецептора фибриногена
EA200200299A1 (ru) НОВЫЕ α-АМИНОКИСЛОТНЫЕ СУЛЬФОНИЛЬНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ИХ СОДЕРЖАЩИЕ
RU2012145950A (ru) Применения ингибиторов dgati
ATE22882T1 (de) Derivate von n-alpha-arylsulfonyl-p-guanidinophenylalanin und arzneimittel mit thrombininhibitor-wirkung.
BR0316586A (pt) Derivados de diidropirano indol-3, 4-dione e derivados de 3-ácido oxoacético 2-hidroximetilindol substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
HUP9903336A2 (hu) Szulfonsav-N-[(amino-imino-metil)-fenil]-aza-heretero-ciklil-amid származékok és az ezeket tartalmazó gyógyszerkészítmények
RU94030812A (ru) Производные фосфоноянтарной кислоты, способ их получения и содержащие эти соединения фармацевтические композиции
RU2009144538A (ru) Новые циклические пептидные соединения
RU95117068A (ru) Антигипертриглицеридемическая композиция, способ ее получения, способ лечения или профилактики гипертриглицеридемии, применение соединений
KR930700468A (ko) 신규의 약학적 활성을 지닌 카테콜 유도체
RU2005137571A (ru) Новые производные диазабициклононена
CA2250861A1 (en) Cyclic adhesion inhibitors
KR880007461A (ko) 헤테로 사이클-치환 디포스포네이트화합물 및 이의 약제학적 조성물
RU2010148387A (ru) Производное фенилпропионовой кислоты и его применение
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
EA200100823A1 (ru) S-нитрозотиолы в качестве агентов для лечения нарушений кровообращения
SE8304513D0 (sv) Derivatvies of omega-amino acids, the preparation and utilisation thereof, and the compositions containing these derivatives
RU2004125609A (ru) Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
EA200600570A1 (ru) Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht
ES2262504T3 (es) Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4.
RU2003104017A (ru) Ингибиторы тромбина, содержащие аминоизохинолиновую группу

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU